Navigation Links
Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
Date:2/16/2011

on and treatment of life-threatening or serious viral infections in immunocompromised patients," said Kenneth I. Moch, President and Chief Executive Officer of Chimerix. "We look forward to working with BARDA to harness the full potential of CMX001 to address the biodefense threat represented by smallpox."

"BARDA's support of the advanced development of CMX001 and their recognition of the role that Chimerix has in helping to assure the Nation's medical preparedness is an important step in addressing the threat of a smallpox attack," said George Painter, Ph.D., Chairman and Chief Scientific Officer of Chimerix. "Chimerix is fully committed to addressing unmet medical needs that have biodefense and global public health implications, especially for the most vulnerable groups in our population including children and the immunocompromised.  We look forward to working collaboratively with BARDA to progress CMX001."

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  

The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases.  Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes si
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
2. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
3. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
4. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
5. Chimerix to Present at Upcoming Investor Conferences
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
8. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
9. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
10. Chimerix Joins International Network of Organizations to Cure Malaria
11. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... 2012  Barbara Walters, Kevin Bacon, Kyra Sedgwick, Wanda Sykes ... in the PBS series Finding Your Roots with ... scientific help of leading personal genetics company, 23andMe.  23andMe ... Your Roots and consulted with show producers to ...
... company Innovative Carbon Limited today announces that they will be ... Graphene, a sheet of carbon just one atom thick, has ... at Manchester University in 2004, for which the team was ... produce it commercially. To support this work the UK ...
... 2012 Arteriocyte, a leading biotechnology company with ... today approval from the Food and Drug Administration ... using its Magellan MAR01™ technology in the treatment ... (IDE 15013) allows Arteriocyte and its clinical partners ...
Cached Biology Technology:23andMe Provides the Science Behind PBS Series "Finding Your Roots with Henry Louis Gates, Jr." With Its Personal Genome Service® 223andMe Provides the Science Behind PBS Series "Finding Your Roots with Henry Louis Gates, Jr." With Its Personal Genome Service® 3UK company to demonstrate their commercially effective graphene production process 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 3
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... University (Canada) have teamed up with genome researchers from ... bone samples from Siberia. The project also involved ... and researchers from Russia, the United Kingdom, France, and ... sequences from a woolly mammoth will be published on ...
... the first solid evidence that still "sharp" older brains store ... discovery is reported by a Johns Hopkins team in the ... prove to apply as well to human brains, it could ... therapies based on what healthy older brains are doing, rather ...
... Unscripted biochemical variations, or noise, leads to oscillations in ... have debated for decades the relative importance of nature ... behaves, and now UCSD scientists report that noise could ... , In a paper in Proceedings of the National ...
Cached Biology News:Scientists sequence DNA of woolly mammoth 2'Sharp' older brains are not the same as younger brains 2Phenotype is influenced by nature, nurture and noise 2
... HT is designed for extended ... HT is ideal for applications ... primer extension assays. The iEMS ... a one-cabinet model, allowing the ...
... Source: Pseudomonas atlantica Description: Beta-Agarase is ... fragments from low-melting-temperature agarose. Beta-Agarase digests ... Tested User Friendly Properties: Heat Inactivation: ... Da Optimum pH: 6.5 Purity: Tested ...
iEMS Thermal Microplate Holder...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
Biology Products: